A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: marks (231), results (1000)

UHS AR 21-22 Quality Account

Description
QUALITY ACCOUNT 2021/22 Part 1: QStaUteAmeLnItToYn qAuaClitCy fOroUm NtheTchief executive 2021/22 1.1 Chief executive’s statement and welcome
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/UHS-AR-21-22-Quality-Account.pdf

DVdSC (weekly cycles 9 onwards) DaratumumabSC-Bortezomib-Dexamethasone Ver1

Description
Chemotherapy Protocol Myeloma DVd SC (weekly) Bortezomib Daratumumab Dexamethasone Cycles 9 onwards Regimen • Myeloma – Bortezomib with daratumumab and dexamethasone Indication • Daratumumab
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdSC-weekly-cycles-9-onwards-DaratumumabSC-Bortezomib-Dexamethasone-Ver1.pdf

InP-Bleomycin-Cisplatin-Etoposide (5 day BEP) Ver1.2

Description
Chemotherapy Protocol GERM CELL BLEOMYCIN-CISPLATIN-ETOPOSIDE (BEP 5 Day) In-Patient Regimen Regimen Germ Cell – InP-Bleomycin-Cisplatin-Etoposide (5
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Germcell/InP-Bleomycin-Cisplatin-Etoposide-5-day-BEP-Ver1.2.pdf

InP RIVAC (66) cytarabine etoposide ifosfamide rituximab

Description
Chemotherapy Protocol LYMPHOMA CYTARABINE-ETOPOSIDE-IFOSFAMIDE-RITUXIMAB (RIVAC) 66 years and above Inpatient Regimen There are multiple versions of this protocol
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-RIVAC-66-cytarabine-etoposide-ifosfamide-rituximab.pdf

InP RIVAC (65) cytarabine etoposide ifosfamide rituximab

Description
Chemotherapy Protocol LYMPHOMA CYTARABINE-ETOPOSIDE-IFOSFAMIDE-RITUXIMAB (RIVAC) 65 years and below Inpatient Regimen There are multiple versions of this protocol
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-RIVAC-65-cytarabine-etoposide-ifosfamide-rituximab.pdf

MDT Leaflet_Young Lives vs Cancer Eligibility Criteria 2021

Description
YOUNG LIVES VS CANCER ELIGIBILITY FOR HEALTH PROFESSIONALS YOUNG LIVES VS CANCER: WHO WE ARE Cancer is shocking, overwhelming, isolating... and
Url
/Media/UHS-website-2019/Docs/Services/Cancer-care/mdt-leaflet-young-lives-vs-cancer-eligibility-criteria-2021.pdf

RFC_PO

Description
Chemotherapy Protocol CHRONIC LYMPHOCYTIC LEUKAEMIA RFC-CYCLOPHOSPHAMIDE-FLUDARABINE-RITUXIMAB (PO) Regimen • CLL – RFC (PO)-Cyclophosphamide-Fludarabine-Rituximab (PO) Indication • Chronic Lymphocytic
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/RFC-PO.pdf

RFC_PO_Split

Description
Chemotherapy Protocol CHRONIC LYMPHOCYTIC LEUKAEMIA CYCLOPHOSPHAMIDE-FLUDARABINE-RITUXIMAB (PO-Split) Regimen • CLL – RFC (PO)-Cyclophosphamide-Fludarabine-Rituximab (PO-Split) Indication • Chronic
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/RFC-PO-Split.pdf

RFC_IV

Description
Chemotherapy Protocol CHRONIC LYMPHOCYTIC LEUKAEMIA CYCLOPHOSPHAMIDE-FLUDARABINE-RITUXIMAB (IV) Regimen • CLL – RFC (IV)-Cyclophosphamide-Fludarabine-Rituximab (IV) Indication • Chronic Lymphocytic Leukaemia
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/RFC-IV.pdf

RFC_IV_Split

Description
Chemotherapy Protocol CHRONIC LYMPHOCYTIC LEUKAEMIA CYCLOPHOSPHAMIDE-FLUDARABINE-RITUXIMAB (IV-Split) Regimen • CLL – RFC (IV)-Cyclophosphamide-Fludarabine-Rituximab (IV-Split) Indication • Chronic
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/RFC-IV-Split.pdf
461 to 470 of 548
Previous … 45 46 47 48 49 … Next